A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases

Completed

• Conditions: Neuroendocrine Tumors, NET

• Registration Number: NCT06853457
• Lead Sponsor: First Affiliated Hospital, Sun Yat-Sen University

Brief Summary

To develop and validate a CT-based transfer learning radiomics model for predicting response to initial TAE in GEP-NETLM patients and compare its performance with traditional radiomics and clinical models.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-01-01
• Primary Completion: 2022-09-30
• Study Completion: 2024-09-01
• Status Verified: 2025-02
• Study First Submitted: 2025-02-23
• Study First Submitted QC: 2025-02-28
• Last Update Submitted: 2025-02-28
• Study First Posted: 2025-03-25
• Last Update Posted: 2025-03-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 257

Inclusion Criteria

• (a) Clinical diagnosed as gastroenteropancreatic neuroendocrine tumor liver metastases; (b) Received initial transarterial embolization therapy; (c) Underwent multi-phase ceCT scans pre-TAE (≤1 month) and post-TAE (4-6 weeks).

Exclusion Criteria

• (a) Neuroendocrine carcinoma (NEC) or other malignancies. (b) Received other liver metastasis treatments. (c) Lack of Multi-phase ceCT scans records. (d) CT images with artifacts or no visible lesions.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The efficacy of TAE	Within one month prior and 4-6 weeks following the initial TAE.	Complete multiphase contrast-enhanced CT images were collected preoperatively and postoperatively. The efficacy of TAE was assessed based on RECIST 1.1 criteria. Patients were classified as objective responders (those achieving complete response \[CR\] or partial response \[PR\]) or non-responders (those with stable disease \[SD\] or progressive disease \[PD\]) through evaluation of target lesions.